Union Pacific Currently Down Eight Consecutive Days, on Track for Longest Losing Streak Since March 2019 — Data Talk
Union Pacific Corporation (UNP) is currently at $229.86, down $2.19 or 0.94%
--Would be lowest close since April 18, 2024, when it closed at $229.81
--Currently down 10 of the past 11 days
--Currently down eight consecutive days; down 6.77% over this period
--Longest losing streak since March 8, 2019, when it fell for eight straight trading days
--Worst eight day stretch since the eight days ending March 20, 2023, when it fell 6.82%
--Down 3.08% month-to-date
--Down 6.42% year-to-date
--Down 16.93% from its all-time closing high of $276.69 on March 30, 2022
--Up 18.36% from 52 weeks ago (May 30, 2023), when it closed at $194.20
--Down 10.53% from its 52-week closing high of $256.91 on Feb. 23, 2024
--Up 19.4% from its 52-week closing low of $192.52 on May 31, 2023
--Traded as low as $228.40; lowest intraday level since April 17, 2024, when it hit $227.87
--Down 1.57% at today's intraday low
All data as of 10:28:20 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
May 28, 2024 10:45 ET (14:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks